TCGA-E9-A1N3-01A-12R-A157-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 35
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.320
- PROTEIN_SECRETION+0.310
- ADIPOGENESIS+0.280
- HEME_METABOLISM+0.210
- FATTY_ACID_METABOLISM+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- MYC_TARGETS_V1+0.180
- PEROXISOME+0.180
- BILE_ACID_METABOLISM+0.170
- MITOTIC_SPINDLE+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.570
- ALLOGRAFT_REJECTION-0.550
- IL6_JAK_STAT3_SIGNALING-0.480
- INFLAMMATORY_RESPONSE-0.480
- TNFA_SIGNALING_VIA_NFKB-0.480
- INTERFERON_GAMMA_RESPONSE-0.450
- IL2_STAT5_SIGNALING-0.400
- TGF_BETA_SIGNALING-0.400
- ANGIOGENESIS-0.360
- COMPLEMENT-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IC-01A-11R-A034-07 | — | B | 0.911 |
| 2 | BS_09R7GDA7 | Embryonal tumors | — | 0.895 |
| 3 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.889 |
| 4 | ULC1533T_S61 | — | cohortA2 | 0.881 |
| 5 | TCGA-EW-A1OX-01A-11R-A144-07 | — | B | 0.880 |
| 6 | TCGA-AO-A0JI-01A-21R-A056-07 | — | B | 0.879 |
| 7 | 103802e1-b3a3-4c55-b094-5011798b6de3 | — | — | 0.879 |
| 8 | TCGA-86-7955-01A-11R-2187-07 | — | cohortA4 | 0.877 |
| 9 | SRR6013568 | — | cohortA2 | 0.872 |
| 10 | MDT-AP-0395 | Med | Medulloblastoma | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.040 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |